Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma

Joseph Tuscano, Mrinal Dutia, Karen Chee, Ann Brunson, Christine Reed-Pease, Mehrdad Abedi, Jeanna L Welborn, Robert T O'Donnell

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

This phase II study evaluated the safety and efficacy of lenalidomide in combination with rituximab in patients with relapsed/refractory, indolent non-Hodgkin lymphoma (NHL). Patients were treated with daily lenalidomide in 28-d cycles and weekly rituximab for 4 weeks. Lenalidomide was continued until progression or unacceptable toxicity. Twenty-two patients were assessed for FCGR3A polymorphisms. Thirty patients were enrolled; 27 were evaluable for response. The overall response rate (ORR) was 74% including 44% complete responses (CR); median progression-free survival (PFS) was 12·4 months. The 13 rituximab refractory patients had an ORR of 61·5% (four CR/unconfirmed CR). The ORR was 77% in the 22 follicular lymphoma patients (nine CR/unconfirmed CR). At a median follow-up time of 43 months, the median duration of response and time to next therapy were 15·4 and 37·4 months, respectively. Most common grade 3/4 adverse events were lymphopenia (45%), neutropenia (55%), fatigue (23%) and hyponatraemia (9%). The ORR and PFS in patients with low-affinity FCGR3A polymorphisms (F/F and F/V) suggest that lenalidomide may improve the activity of rituximab in these patients. These data suggest that combining lenalidomide with rituximab can produce durable responses with acceptable toxicity in patients with indolent NHL.

Original languageEnglish (US)
Pages (from-to)375-381
Number of pages7
JournalBritish Journal of Haematology
Volume165
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Non-Hodgkin's Lymphoma
Disease-Free Survival
lenalidomide
Rituximab
Lymphopenia
Follicular Lymphoma
Hyponatremia
Neutropenia
Reaction Time
Fatigue
Safety

Keywords

  • Fc receptor polymorphisms
  • Lenalidomide
  • Lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. / Tuscano, Joseph; Dutia, Mrinal; Chee, Karen; Brunson, Ann; Reed-Pease, Christine; Abedi, Mehrdad; Welborn, Jeanna L; O'Donnell, Robert T.

In: British Journal of Haematology, Vol. 165, No. 3, 2014, p. 375-381.

Research output: Contribution to journalArticle

@article{d5e42e40f70141128299ec08def31a3f,
title = "Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma",
abstract = "This phase II study evaluated the safety and efficacy of lenalidomide in combination with rituximab in patients with relapsed/refractory, indolent non-Hodgkin lymphoma (NHL). Patients were treated with daily lenalidomide in 28-d cycles and weekly rituximab for 4 weeks. Lenalidomide was continued until progression or unacceptable toxicity. Twenty-two patients were assessed for FCGR3A polymorphisms. Thirty patients were enrolled; 27 were evaluable for response. The overall response rate (ORR) was 74{\%} including 44{\%} complete responses (CR); median progression-free survival (PFS) was 12·4 months. The 13 rituximab refractory patients had an ORR of 61·5{\%} (four CR/unconfirmed CR). The ORR was 77{\%} in the 22 follicular lymphoma patients (nine CR/unconfirmed CR). At a median follow-up time of 43 months, the median duration of response and time to next therapy were 15·4 and 37·4 months, respectively. Most common grade 3/4 adverse events were lymphopenia (45{\%}), neutropenia (55{\%}), fatigue (23{\%}) and hyponatraemia (9{\%}). The ORR and PFS in patients with low-affinity FCGR3A polymorphisms (F/F and F/V) suggest that lenalidomide may improve the activity of rituximab in these patients. These data suggest that combining lenalidomide with rituximab can produce durable responses with acceptable toxicity in patients with indolent NHL.",
keywords = "Fc receptor polymorphisms, Lenalidomide, Lymphoma, Rituximab",
author = "Joseph Tuscano and Mrinal Dutia and Karen Chee and Ann Brunson and Christine Reed-Pease and Mehrdad Abedi and Welborn, {Jeanna L} and O'Donnell, {Robert T}",
year = "2014",
doi = "10.1111/bjh.12755",
language = "English (US)",
volume = "165",
pages = "375--381",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma

AU - Tuscano, Joseph

AU - Dutia, Mrinal

AU - Chee, Karen

AU - Brunson, Ann

AU - Reed-Pease, Christine

AU - Abedi, Mehrdad

AU - Welborn, Jeanna L

AU - O'Donnell, Robert T

PY - 2014

Y1 - 2014

N2 - This phase II study evaluated the safety and efficacy of lenalidomide in combination with rituximab in patients with relapsed/refractory, indolent non-Hodgkin lymphoma (NHL). Patients were treated with daily lenalidomide in 28-d cycles and weekly rituximab for 4 weeks. Lenalidomide was continued until progression or unacceptable toxicity. Twenty-two patients were assessed for FCGR3A polymorphisms. Thirty patients were enrolled; 27 were evaluable for response. The overall response rate (ORR) was 74% including 44% complete responses (CR); median progression-free survival (PFS) was 12·4 months. The 13 rituximab refractory patients had an ORR of 61·5% (four CR/unconfirmed CR). The ORR was 77% in the 22 follicular lymphoma patients (nine CR/unconfirmed CR). At a median follow-up time of 43 months, the median duration of response and time to next therapy were 15·4 and 37·4 months, respectively. Most common grade 3/4 adverse events were lymphopenia (45%), neutropenia (55%), fatigue (23%) and hyponatraemia (9%). The ORR and PFS in patients with low-affinity FCGR3A polymorphisms (F/F and F/V) suggest that lenalidomide may improve the activity of rituximab in these patients. These data suggest that combining lenalidomide with rituximab can produce durable responses with acceptable toxicity in patients with indolent NHL.

AB - This phase II study evaluated the safety and efficacy of lenalidomide in combination with rituximab in patients with relapsed/refractory, indolent non-Hodgkin lymphoma (NHL). Patients were treated with daily lenalidomide in 28-d cycles and weekly rituximab for 4 weeks. Lenalidomide was continued until progression or unacceptable toxicity. Twenty-two patients were assessed for FCGR3A polymorphisms. Thirty patients were enrolled; 27 were evaluable for response. The overall response rate (ORR) was 74% including 44% complete responses (CR); median progression-free survival (PFS) was 12·4 months. The 13 rituximab refractory patients had an ORR of 61·5% (four CR/unconfirmed CR). The ORR was 77% in the 22 follicular lymphoma patients (nine CR/unconfirmed CR). At a median follow-up time of 43 months, the median duration of response and time to next therapy were 15·4 and 37·4 months, respectively. Most common grade 3/4 adverse events were lymphopenia (45%), neutropenia (55%), fatigue (23%) and hyponatraemia (9%). The ORR and PFS in patients with low-affinity FCGR3A polymorphisms (F/F and F/V) suggest that lenalidomide may improve the activity of rituximab in these patients. These data suggest that combining lenalidomide with rituximab can produce durable responses with acceptable toxicity in patients with indolent NHL.

KW - Fc receptor polymorphisms

KW - Lenalidomide

KW - Lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84898467895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898467895&partnerID=8YFLogxK

U2 - 10.1111/bjh.12755

DO - 10.1111/bjh.12755

M3 - Article

C2 - 24606326

AN - SCOPUS:84898467895

VL - 165

SP - 375

EP - 381

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -